A Future for Biosimilars and Biobetters

With growing concern for rising healthcare cost comes a growing demand for more affordable drugs, and a market for developing them. Biobetters and biosimilars are gaining the attention of both small and large pharma companies as an area of opportunity to deliver more cost-effective treatments. As the patents for many originator pharmaceuticals are approaching expiry, now, more than ever, biosimilars are becoming an opportunity for profit growth.

Many companies are already planning for the future of biosimilars and biobetters, whether that be in stocks, research and development for new drugs, or international expansion – biosimilars will become an intricate part of our healthcare system, similar to their role in the EU.

So will pharmaceutical companies choose to develop biosimilars or biobetters? Furthermore, how does one even define a biobetter, seeing as there is no legal or regulatory definition currently in place? Outsourcing-pharma.com states, “A biobetter improves on the original biologic by, for example, reducing the side-effect profile.” The site also discusses how biobetters will produce a need for clinical trials, which opens new business opportunities for CROs.

The Third Annual Business of Biosimilars and Biobetters event provides you with the opportunity to hear industry experts share the development and commercialization strategies that matter most.

Share this article with your social network, just click below to share now!

Share |